Medical Oncology, NHG Cancer Institute
Medical Oncology, Tan Tock Seng Hospital
Medical Oncology, Woodlands Hospital
Clinical Director (Clinical Trials)
Clinical Research & Innovation Office (CRIO), Tan Tock Seng Hospital
Clinical Director (Clinical Trials)
Clinical Research & Innovation Office (CRIO), Tan Tock Seng Hospital
Asst Prof Jens Samol is a Senior Consultant with the Department of Medical Oncology at Tan Tock Seng Hospital (TTSH) in Singapore. He is a fellow of the Academy of Medicine Singapore for the Chapter of Medical Oncology & Chapter of Genomic Medicine. Dr Samol received his medical degree, equivalent to MBBS, from the Free University of Berlin/ Charité. Dr Samol holds specialists' certificate in Medical Oncology and achieved his Doctor in Medicine, equivalent to PhD, with Summa Cum Laude.
Asst Prof Samol treats patients with all types of solid cancers as well as lymphoid neoplasms. He has a particular interest in Thoracic Cancers, Head & Neck Cancers, Gastrointestinal Cancers (including HIPEC), Sarcoma, and Lymphoma. Dr Samol is the Clinical Lead for Thoracic Cancers, Lymphoma (within Medical Oncology) and Sarcoma as well as the Clinical Lead for Genetic Counselling and Clinical Cancer Genetics & Genomics Service at TTSH. Dr Samol is the Director for Clinical Trials (CRIO), Co-Director (TTSH) for P.H.Feng Research Centre and is the Clinical Research Lead of the Medical Oncology Department at TTSH.
Asst Prof Samol holds a faculty appointment as an Assistant Professor at Lee Kong Chian School of Medicine, Singapore, as well as an Assistant Professor of Oncology at Johns Hopkins University School of Medicine, Baltimore, USA.
Tan Tock Seng Haemato-Oncology and Palliative Medicine Departments are an ESMO Accredited Designated Centre for Integrated Care and the contact person is Dr Samol.
Dr Samol practices a patient-centred approach and uses the latest evidence to achieve the best outcome for all patients treated within NHG Health.
Publications
1. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
2. Whole-exome sequencing of BRCA-negative breast cancer patients and case-control analyses identify variants associated with breast cancer susceptibility
3. Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
4. 652O Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC)
5. Early COVID-19 booster is beneficial in cancer patients
6. Correction: Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer
7. Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer
8. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
9. Machine learning unveils an immune-related DNA methylation profile in germline DNA from breast cancer patients.
10. Beyond a vestigial organ: effects of the appendix on gut microbiome and colorectal cancer.
11. Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.
